Crohn’s disease market grows to $13.8bn—can NeuroScientific’s stem cell pivot capture real value?

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has made a decisive clinical transition with the acquisition of Isopogen WA Ltd and full rights to the patented StemSmart stem cell platform. Its first focus: fistulising Crohn’s disease, a debilitating subtype of inflammatory bowel disease where conventional therapies often fail. With a new Special Access Scheme now underway in Australia, the biotech firm is seeking to carve out space in a global Crohn’s disease market projected to hit US$13.8 billion by 2026.

How large is the global Crohn’s disease therapeutics market and what patient subgroups can NSB’s StemSmart platform realistically target?

Fistulising Crohn’s disease affects nearly one-third of Crohn’s patients and remains a notoriously difficult condition to treat, especially when resistant to steroids, biologics, or immunosuppressants. This refractory patient segment represents a high-unmet-need niche where existing drug pipelines have failed to deliver long-term remission or meaningful quality of life improvements. NeuroScientific Biopharmaceuticals is targeting exactly this subset with its mesenchymal stromal cell (MSC) therapy—engineered to activate in inflamed tissues and support both immune modulation and tissue regeneration.

Early clinical data supports this approach. In a prior Phase 2 trial of 21 biologic-refractory Crohn’s patients, 78% of subjects receiving StemSmart MSCs showed a reduction in Crohn’s Disease Activity Index (CDAI) scores, with 44% achieving full remission. The current Special Access Program being conducted in Australia will test these cells in a more targeted setting: patients with non-healing perianal fistulas. If clinical benefit is demonstrated in just four patients, performance-linked milestones within the acquisition agreement will activate—setting the stage for broader trial progression.

The broader opportunity extends far beyond Crohn’s alone. StemSmart’s underlying technology is applicable to multiple high-value immunological markets, including graft-versus-host disease (GvHD), kidney transplant rejection, and chronic obstructive pulmonary disease (COPD). Collectively, these indications could push the total addressable market past US$50 billion by 2034. But Crohn’s, particularly its refractory and fistulising subtypes, offers the most immediate pathway to patient impact and clinical validation.

Industry sentiment surrounding mesenchymal stem cells has shifted notably since the U.S. FDA approved the first allogenic MSC therapy for pediatric steroid-refractory GvHD in December 2024. That regulatory milestone, granted to Mesoblast Ltd, sparked renewed investment interest in cell-based immunotherapies and underscored the commercial feasibility of MSC products when paired with strong clinical data. NeuroScientific’s entry into this space aligns with that momentum and positions it well for fast-track regulatory frameworks in Australia.

Going forward, success in the ongoing SAS will be pivotal for NeuroScientific Biopharmaceuticals. A positive response could accelerate Phase 1/2 trial launches or strategic partnerships with global biopharma players. The platform’s flexibility and early safety data offer attractive attributes—but as always in early-stage biotech, progress will depend on clear, reproducible clinical outcomes.